TB

This new roadmap for 2011-2015 follows on the Global Plan to Stop TB 2006-2015 while setting new and more ambitious targets for the next five years. The action plan, for the first time, identifies all the research gaps that need to be filled to bring rapid TB tests, faster treatment regimens and a fully effective vaccine to market. It also shows public health programmes how to drive universal access to TB care, including how to modernize diagnostic laboratories and adopt revolutionary TB tests that have recently become available.

This brochure presents guidance to limit liver toxicity in the HIV-positive patient with latent TB infection.

The white paper, or policy document, outlines the strategic vision of NCHHSTP for reducing health disparities and promoting health equity among populations affected by these diseases. NCHHSTP is committed to promoting awareness, stakeholder and community engagement, and action on factors that can affect the nation and the world's health; to addressing these factors in the policy, practice, and research activities of NCHHSTP; and to building partnerships on every level.

Delivering HIV Rapid Test Results: Experiences from the Field is a short (approximately 30 minute) video that combines real stories from providers delivering rapid test results and clients learning their test results, as well as scripted vignettes that illustrate key points. It is designed so that it can be used both for individual study as well as in a group learning setting. There is also an accompanying 26-page discussion and resource guide.

Community health centers (CHCs) are important facilities which implement routine HIV testing consistent with the 2006 recommendations issued by the Centers for Disease Control and Prevention (CDC). This document provides an overview of general protocol elements for facility-based HIV testing and post-test counseling.

This report highlights the issues surrounding high prices and poor supply of the drugs needed to treat drug-resistant tuberculosis (DR-TB). The report provides an overview of available drug-resistant TB medicines, including drug sources, quality status, and price.

The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.

This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.

The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.

This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.

The challenges of TB-HIV co-Infection are highlighted in this issue. Psychosocial aspects of HIV diagnosis and self-awareness are also discussed.

The guidelines show how people with HIV can be protected from tuberculosis with regular, low-cost preventive medication. The guidelines present a set of recommendations that will help reduce TB disease in people living with HIV, their families and communities through a combination of screening for TB and provision of IPT.